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Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of 
islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and 
heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of 
islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this 
study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen 
alleles, hemoglobinA1c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific auto-
antibody in newly diagnosed T1DM patients (duration shorter than half year) was 73% in East China. According to binary lo-
gistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As 
the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies 
against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell 
destruction. Autoantibodies can facilitate the identification of classic T1DM from other subtypes and predict the progression of 
islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the 
disease, we should take more factors into consideration when identifying type 1 diabetes mellitus. 
autoantibodies, heterogeneity, islet failure, type 1 diabetes 
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Type 1 diabetes mellitus (T1DM) is a T-cell-mediated au-
toimmune disease in which insulin-producing beta cells in 
pancreatic islets of Langerhans are selectively destroyed, 
leading to insulin deficiency and dysregulation of glucose 
metabolism (Atkinson and Maclaren, 1994; Eisenbarth, 
1986; Gillespie, 2006; Zhang et al., 2008). The incidence of 
diabetes highly varies in different countries, and this is 
probably related to genetic and environmental factors, such 
as nutrition or lifestyle (Patterson et al., 2001). It is esti-
mated that 30%–50% of the genetic risk for type 1 diabetes 
can be attributed to the human leukocyte antigen alleles 
(HLA) region (Noble et al., 1996). The strongest genetic 
association for type 1 diabetes is HLA class II genes, while 
HLA class I alleles also influence susceptibility to T1DM 
and humoral autoimmunity. Autoantibodies against insulin 
(IAA), islet cell (ICA), glutamate decarboxylase (GADA), 
islet antigen-2 (IA-2A), and zinc transporter 8 (ZnT8A) 
might appear in patients months or even years prior to di-
agnosis of T1DM. The increase of the persistent is-
let-specific autoantibodies was positively correlated to the 
probability of developing disease (Bingley et al., 2006; 
Gale, 1994; Orban et al., 2009; Siljander et al., 2009;  
Verge et al., 1996; Ziegler, 2004). The identification and 
study of these autoantibodies associated with T1DM 
(Baekkeskov et al., 1990; Bonifacio et al., 1995; Bottazzo et al., 
1974; Palmer et al., 1983; Wenzlau et al., 2007) have em-
phasized their roles as biomarkers in diagnosis (Wasserfall 
and Atkinson, 2006), prognosis, patient treatment stratifica-
tion (Christie et al., 2002; Hagopian et al., 2011), tolerating 
therapies as well as providing insights into pathophysiology 
of the disease (Ludvigsson et al., 2008). Consequently, with 
highly sensitive laboratory assays, the autoantibodies posi-
tivity among European T1DM patients at diagnosis was 
nearly 98% (Wenzlau et al., 2007). However, the autoanti-
body assays were often negative in Asian T1DM patients. It 
might due to the unsensitive or unspecific assays, or testing 
far from diagnosis as antibody titers diminish, yet-to-be- 
identified auto-antigens, or foremost heterogeneity of islet 
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autoantibodies in Chinese population (Lu et al., 2012;  
Wang et al., 2007; Zhou et al., 2013). 
There are many facets of diabetes with great heterogene-
ity. T1DM indeed represents a heterogeneous disease which 
manifests remarkable diversity in pathogenic processes, 
genetics and phenotypic characteristics. The diagnosis for 
T1DM in most epidemiological research depends on clinical 
characteristics, which are affected by phenotypic variation. 
Lower incidence of T1DM in China was reported and 
whether the wide variation disturbed the clinical diagnosis, 
especially in adult-onset type 1 diabetes, still not be eluci-
dated. Therefore, we analyzed the heterogeneity of  
islet-specific autoantibodies; clinical characteristics and the 
progression of islet failure in Chinese cohort with 1,291 
T1DM patients. We expect this will help the design of epi-
demiological study for type 1 diabetes in China and the 
customized medication in the future. 
RESULTS 
Combined detection of enzyme linked immunosorbent 
assay (ELISA) and radioimmunoassay (RIA) improve 
the prevalence of islet autoantibodies in Chinese T1DM 
patients 
The positivity of GADA, ZnT8A, and IA2A were 53.7%, 
40.7% and 33.8% respectively among 1,206 patients (85 
subjects of the whole sample had not been tested, Figure 
1A). The autoantibody positivity of newly diagnosed dia-
betic patients (duration shorter than half a year) was 72.6%, 
which didn’t show significant difference from the total 
sample (71.5%, P=0.230). Meanwhile, three antibodies 
(GADA, ICA, and IA2A) were detected by ELISA in 432 
patients of whole subject and the frequency was 56.7%, 
24.1% and 26.6%, respectively (Figure 1B). Apparently, 
RIA showed better sensitivity and efficacy than ELISA 
(71.5% vs. 67.8% for at least 1 autoantibody positive, 
P<0.001, Figure S1 in Supporting Information). When tak-
ing these two methods combined, the sensitivity and effica-
cy were further improved (P<0.001, Figure 1C). 
Islet function and islet-specific autoantibody positivity 
declined faster in classic T1DM compared with latent 
autoimmune diabetes of adult (LADA) patients 
As shown in Figure 2, the prevalence of GADA, ZnT8A, 
IA2A decreased significantly in classic T1DM patients suf-
fered longer than five years (P=0.026, P=0.026 and 
P=0.005 respectively, Figure 2A). Obviously, long-standing 
classic T1DM had lower fasting and stimulated C-peptide 
compared to those suffered shorter than five years (P<0.001 
and P=0.002, Figure 2B). However, among LADA patients, 
neither the frequency of autoantibodies (ZnT8A, GADA 
and IA2A; P=0.165, P=0.554 and P=0.712 respectively, 
Figure S2A in Supporting Information) nor the fasting and 
stimulated C-peptide changed depending on the duration of 
diabetes (P=0.342 and P=0.336, Figure S2B in Supporting 
Information). 
Comparison between autoantibodies-positive and auto-
antibodies-negative patients 
More female and short-duration patients were found in the 
autoantibodies-positive group, in comparison with the au-
toantibodies-negative group (Table 1, P=0.042 and P= 
0.018). Most importantly, both fasting C-peptide levels and 
area under the curve (AUC) of C-peptide were significantly 
lower in autoantibodies-positive patients (P<0.001 and 
P<0.001). Notably, GADA-positive patients were shown to 
have higher levels of high-density lipoprotein (HDL) 
(P=0.005), and tended to be leaner (P=0.002). Higher fre-
quency of HLA gene haplotype HLA-A*11:01-DRB1* 
09:01 and HLA-A*11:01-DRB1*03:01 was found in GADA- 
Table 1  Comparison between autoantibodies- positive and autoantibodies-negative patientsa) 
Variable 
ZnT8A GADA IA2A P value 
+  +  +  ZnT8A GADA IA-2A 
n 486 707 640 551 408 798   
Female-n (%) 254 (53.0) 328 (47.0) 332 (52.8) 251 (45.9) 212 (53.0) 372 (47.7) 0.042** 0.018** 0.085** 
Age (years) 30.3±18.9 30.9±17.7 30.4±19.3 31.4±16.9 28.8±20.4 31.8±16.9 0.585* 0.339* 0.013* 
Duration (months) 25.5±57.7 37.8±71.4 28.4±61.0 39.3±73.4 23.9±58.1 37.6±70.5 0.004* 0.016* 0.002* 
Age of onset (years) 28.1±19.1 27.5±16.9 27.9±19.1 27.8±16.3 26.9±20.3 28.3±16.3 0.594* 0.887* 0.250* 
BMI (kg m2) 20.7±4.5 21.1±4.0 20.6±4.2 21.4±4.1 20.6±4.9 21.1±3.7 0.188* 0.002* 0.108* 
MAP (mmHg) 89.3±12.2 90.9±12.3 88.4±11.8 92.7±12.3 89.1±12.2 90.8±12.2 0.042* 0.000* 0.034* 
HDL (mmol L1) 1.3±0.5 1.3±0.6 1.4±0.7 1.2±0.4 1.3±0.7 1.3±0.5 0.921* 0.005* 0.152* 
HbA1C (%) 10.4±3.2 10.8±3.4 10.4±3.2 10.8±3.5 10.2±3.2 10.9±3.4 0.091* 0.163* 0.007* 
FCP (pmol L1) 183±163 250±224 180±164 278±235 180±157 245±221 <0.001* <0.001* <0.001* 
AUC of C-peptide (pmol mL2 min2) 87.7±67.3 124.4±115.6 82.2±76.1 149.7±119.0 91.9±86.9 119.6±107.7 <0.001* <0.001* 0.006* 
HLA-A*11:01-DRB1*09:01 -n (%) 7 (8.1) 12 (6.7) 16 (10.3) 3 (2.7) 14 (12.0) 8 (4.5) 0.680** 0.018** 0.022** 
HLA-A*11:01-DRB1*03:01 -n (%) 5 (5.7) 12 (6.6) 14 (8.9) 3 (2.6) 8 (8.9) 9 (4.9) 0.798** 0.035** 0.238** 
a) Data are expressed as n (%) or mean ± SD. The statistical significance is determined by *, independent samples t test, **, 2 test. P value is indicated. 
FCP, fasting C-peptide.  
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Figure 1  A and B, Positive rate of islet autoantibodies detected by RIA and ELISA respectively. C, Different positive rate for at least one islet antibody 
calculated by ELISA, RIA or combined ELISA and RIA. white bars=GADA, IAA, ICA, IA2A by ELISA; black bars=GADA, IA2A, ZnT8A by RIA; loxot-
ic bars=GADA, IA2A, ZnT8A by RIA and IAA, ICA by ELISA. 
positive patients (P=0.018 and P=0.035 respectively). Dis-
appointedly, differences in clinical manifestation were not 
observed between autoantibodies-positive and autoantibod-
ies-negative patients. 
The frequency of autoantibodies was negatively corre-
lated with islet function  
Among 1,291 subjects, the autoantibodies of 1,232 subjects 
were determined by RIP or ELISA. According to Table 2, 
type 1 diabetes was heterogeneous. In autoantibody-positive 
group, LADA patients, compared with those classic T1DM 
patients, were older (P<0.001, Table 2), with higher body 
mass index (BMI) (P<0.001, Table 2) and had better islet 
function (P<0.001, Figure 3), higher levels of mean arterial 
pressure (MAP) (P<0.001, Table 2), low density lipoprotein 
(LDL) (P=0.001, Table 2) and lower hemoglobinA1c 
(bA1C) (P<0.001, Table 2). In addition to these parameters, 
they had lower incidence of viral infection (P=0.009, Table 
2) and diabetic ketoacidosis (DKA) (P<0.001, Table 2). The 
frequency of ZnT8A, GADA, IA2A and ICA in LADA pa-
tients was between the 1Ab+ and the 2Ab+ group of classic 
T1DM patients (P<0.001, Table 2), whereas the frequency 
of IAA was as high as the 2Ab+ group and significantly 
higher than the 1Ab+ group (P<0.001, Table 2). Even 
among the classic T1DM patients, the clinical characteris-
tics are significantly divergent. The patients in Ab group 
had islet function as good as in LADA patients (P=0.881, 
Figure 3). They had neither metabolic nor immune factors 
while patients in the 2Ab+ group, showed the highest fre-
quency of autoantibodies, the youngest age of onset 
(P<0.001, Table 2), the lowest islet function (P<0.001, Ta-
ble 2), the lowest BMI (P<0.001, Table 2), the lowest MAP 
(P<0.001, Table 2) and LDL (P<0.001, Table 2). 
Autoantibodies especially GADA were the risk factors of 
islet function 
Compared to patients with better islet function, those with 
worse islet function were leaner (P<0.001, Table 3) and had 
a longer duration (P<0.001, Table 3), with more autoanti-
bodies (P<0.001, Table 3) and higher frequency of autoan-
tibodies (P<0.001, Table 3). Further analysis of logistic 
regression demonstrated that the duration and the autoanti-
bodies were the risk factors to islet failure (Table 3, Table 
S1 in Supporting Information) while BMI was the protec-
tive factor (OR=0.796, P<0.001, Table 3). The positive rate 
of ZnT8A, IA2A and GADA were negatively correlated 
with level of fasting C-peptide (P<0.001, P<0.001, 
P<0.001, respectively, Table S3 in Supporting Information). 
However, no significant difference of the prevalence of 
ZnT8A was observed in the level of AUC of C-peptide 
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Table 2  Correlation between different phenotypes in T1DM patientsa) 
Variable 2Ab+ 1Ab+ Ab LADA P value 
n 437 325 257 213  
Female-n (%) 224 (52.2) 150 (46.6) 112 (44.1) 115 (54.5) 0.059* 
Age (year) 23.2±15.3 28.1±15.7 29.9±15.9 52.4±13.5 <0.001* 
Duration (month) 24.0±57.6 41.3±72.9 38.2±79.4 32.5±49.8 0.007* 
Age of onset (year) 20.3±13.5 23.5±14.5 26.5±14.2 51.1±13.9 <0.001* 
BMI (kg m2) 19.4±3.9 20.5±3.9 21.3±3.9 23.7±3.9 <0.001* 
MAP (mmHg) 86.7±10.6 89.5±11.0 92.5±11.0 94.9±12.4 <0.001* 
HDL (mmol L1) 1.4±0.8 1.3±0.4 1.2±0.4 1.3±0.3 0.029* 
LDL (mmol L1) 2.6±0.9 2.8±1.2 2.8±1.1 2.9±0.9 0.010* 
RBP (mg L1) 30.8±16.7 29.4±18.6 31.6±14.8 43.2±23.8 <0.001* 
BUN (mmol L1) 21.6±203.2 6.4±18.0 4.7±2.0 6.0±2.6 0.608* 
Cr (μmol L1) 56.4±32.3 58.0±50.5 55.0±30.8 70.3±43.1 0.071* 
Virus Infection -n (%) 47 (16.7) 33 (18.9) 29 (18.8) 3 (3.6) 0.009** 
Ketosis Acid -n (%) 195 (55.1) 123 (55.7) 104 (58.1) 25 (26.6) <0.001** 
HbA1C (%) 11.2±2.9 11.2±3.2 11.5±3.7 8.5±2.9 <0.001* 
ZnT8A -n (%) 305 (71.9) 78 (24.8) 0 (0) 103 (49.8) <0.001** 
GADA -n (%) 365 (84.9) 135 (43.3) 0 (0) 140 (67.3) <0.001** 
IA-2A -n (%) 269 (62.6) 42 (13.2) 0 (0) 97 (46.6) <0.001** 
ICA -n (%) 116 (39.1) 24 (11.3) 0 (0) 33 (29.5) <0.001** 
IAA -n (%) 85 (29.2) 20 (9.6) 0 (0) 39 (34.8) <0.001** 
HLA-A*30:01-DRB1*07:01 -n (%) 7 (6.0) 12 (16.7) 5 (9.1) 2 (4.8) 0.065** 
HLA-A*24:02-DRB1*09:01 -n (%) 11 (9.8) 5 (7.0) 5 (9.1) 8 (21.1) 0.134** 
HLA-A*11:01-DRB1*09:01 -n (%) 13 (11.6) 4 (5.6) 0 (0) 2 (5.4) 0.043** 
HLA-A*11:01-DRB1*03:01 -n (%) 10 (8.8) 6 (8.2) 1 (1.8) 0 (0) 0.096** 
a) Data are expressed as n(%) or mean±SD. P value, * is the result of non-parametric test or ANOVA test, ** is the result of 2 test. RBP, retinol-binding 
protein. BUN, blood urine nitrogen. Cr, creatinine. 
Table 3  Correlation between different fasting C-peptide levels in T1DMa) 
Variable 
Levels of fasting C-P (pmol L1) P value 
<70 70–170 170–320 >320 P1 OR (95%CI) P2 
n 215 212 208 203 
  
 
Age (years) 28.9 (26.4–31.4) 25.2 (23.0–27.4) 26.2 (24.0–28.5) 29.9 (27.8–32.0) 0.013* Not tested 
Female-n(%) 112 (52.6%) 103 (48.8%) 84 (40.8%) 79 (39.1%) 0.015** Not tested 
Age of onset (years) 23.0 (20.8–25.2) 23.2 (21.2–25.3) 23.9 (21.8–26.1) 28.2 (26.2–30.3) 0.002 * 0.972 (0.958–0.987) <0.001 
Duration (months) 57.0 (43.8–70.2) 17.9 (10.8–25.3) 18.3 (11.8–24.9) 17.0 (11.5–22.5) <0.001* 1.147 (1.082–1.216) <0.001 
BMI (kg m2) 
LDL (mmol L1) 
Cr (μmol L1) 





























ZnT8 positive -n (%) 73 (37.6%) 93 (48.2%) 72 (38.3%) 44 (23.5%) <0.001** 2.39 (1.449–3.942) 0.001 
GAD positive -n (%) 119 (61.0%) 127 (65.5%) 111 (58.7%) 64 (34.8%) <0.001** 2.505 (1.57–3.996) <0.001 
IA2 positive -n (%) 65 (32.8%) 77 (39.1%) 74 (38.7%) 32 (17.0%) <0.001** 2.851 (1.656–4.91) <0.001 
Number of positive Ab≥1 -n (%) 160 (80.4%) 160 (80.0%) 139 (70.9%) 95 (50.0%) <0.001** 3.058 (1.781–5.251) <0.001 
Number of positive Ab≥2 -n (%) 76 (38.2%) 96 (48.0%) 81 (41.3%) 35 (18.4%) <0.001** 3.22 (2.0–5.185) <0.001 
a) Data are expressed as mean (95% CI range) or n (%). P1, * is the result of non-parametric test or ANOVA test. ** is the result of 2 
test; P2 is the result of multiple factor logistic regression. For multiple factor logistic regression, analyses of BMI, LDL, Cr, BUN, ZnT8, 
GADA, IA-2, Number of positive Ab≥1 and Number of positive Ab≥2 were adjusted for Age of onset and duration. 
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Figure 2  A, Heterogeneity of positive rate (%) of islet autoantibodies 
among different durations. B, Heterogeneity of islet function among dif-
ferent durations. black square=GADA; black circle=ZnT8A; black trian-
gle=IA-2A; white square=AUC of C-peptide (×102 pmol L1 min1); white 
circle=Fasting C-peptide (pmol L1); bars=95% CI range. P value was 
indicated. (vs. the group with duration longer than 61 months). C-P, 
C-peptide; IA2A, islet antigen-2 autoantibody; NS, no statistical signifi-
cance. 
(P=0.097, Table S1 in Supporting Information).  
Taken the clinical characteristics into consideration, we 
further evaluated the correlation factors of fasting C-peptide 
in different clinical phenotypes using Binary Logistic re-
gression model (Table 4). It suggested that in 2Ab+, the pa-
tients with longer duration (OR=1.037, P=0.035, Table 4), 
haplotype of HLA-A*11:01-DRB1*09:01(OR=6.376, P= 
0.001, Table 4) were prone to have faster islet failing pro-
cess. As for 1Ab+, GADA positivity was the risk factor of 
islet function (OR=2.678, P=0.032, Table 4), while ICA 
positivity was the protective factor (OR=0.188, P=0.046, 
Table 4). In Ab group, those with lower BMI (P=0.008, 
Table 4) were inclined to have worse islet function. Among 
the LADA patients, the risk factors were longer duration 
(OR=1.014, P=0.022, Table 4) and GADA positivity 
(OR=5.726, P=0.004, Table 4). 
DISCUSSION 
It was well known T1DM-associated autoantibodies against 
islet-specific autoantigens were not always detectable in all 
T1DM patients, however the prevalence of islet autoanti-
bodies in Asian population was significantly lower than that  
 
Figure 3  A, Heterogeneity of fasting C-peptide (pmol L1) among dif-
ferent clinical phenotypes. B, Heterogeneity of AUC of C-peptide (×102 
pmol L1 min1) among different clinical phenotypes. bars=95% CI range. 
P value was indicated. Ab, antibody. NS, no statistical significance. 
in Caucasian population. It might due to (i) unreliable as-
says with low sensitivity or specificity, (ii) longer duration 
with lower titer of antibodies, (iii) yet-to-be-identified au-
to-antigens, or foremost (iv) heterogeneity of islet autoanti-
bodies among Chinese group (Ludvigsson et al., 2008). We 
detected the islet autoantibodies with the standardized as-
say, RIA, which may be both sensitive and efficacious. 
When considering the detective stability of IAA and ICA, 
we used ELISA instead of RIA. Combining these two 
methods together, the testing power was further improved. 
It suggested that the more autoantibodies detected by stand-
ard methods, the better results we could get. To investigate 
whether the frequency of autoantibodies declines along with 
the interval between disease onset and laboratory test, we 
further analyzed the samples from patients with durations 
shorter than six months, the results showed no significantly 
difference (73.0% vs. 71.5%, P=0.230). Above all, the 
yet-to-be-identified auto-antigens and the heterogeneity of 
islet autoantibodies among Chinese might have crucial im-
pact on the race diversity of the prevalence of antibodies. 
In the present cohort, there was no significant decrease of 
positivity for ZnT8A, IA2A and GADA within five years 
after diagnosis. This was in line with the observed pattern  
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Table 4  Correlation factors analysis of fasting C-peptide in different T1DM phenotypesa) 
Variable Wald OR (95%CI) P value 
LADA    
Duration 5.214 1.014 (1.002–1.027) 0.022 
GADA 8.225 5.726 (1.738–18.871) 0.004 
ZnT8 0.013 0.942 (0.339–2.616) 0.539 
ICA 0.008 1.05 (0.369–2.989) 0.927 



















































ICA 0.153 0.827 (0.319–2.413) 0.695 
a) Data are expressed as mean (95% CI range). P value is the result of Binary Logistic regression. For LADA, the analyses of GADA, 
ZnT8, and ICA were adjusted for duration; For AbT1D, the analyses of BMI and DKA were adjusted for duration; For 1Ab+T1D, the 
analyses of GADA, ZnT8, ICA and DKA were adjusted for duration; For 2Ab+T1D, the analyses of GADA, ZnT8, ICA and 
HLA-A*11:01-DRB1*09:01 were adjusted for duration. 
 
(Nielsen et al., 2011). Among classic T1D patients, their 
autoantibodies declined significantly during five years after 
they were diagnosed. The mean age at which a patient was 
diagnosed with diabetes was 27.6±17.7 years, which was 
similar to the observation in the report, Tridgell et al. 
(Tridgell, 2011). They found that for individuals who were 
diagnosed with diabetes at age 14 or older, the prevalence 
for GADA changed little during the first five years after 
diagnosis, as we demonstrated. Whereas for IA2A, they 
found that the change in antibody frequency was similar 
despite age of diagnosis during the next eight years from 
onset of disease, which was different from our findings. In 
this study we had further demonstrated that autoantibody 
diminishing and islet failure in classic type 1 diabetic were 
faster than LADA. 
To explore the heterogeneity of clinical phenotypes in 
Chinese T1DM, we compared our cohort with other T1DM 
studies. In contrast to the Sweden Study (Ludvigsson et al., 
2013), the classic T1DM patients with autoantibody positiv-
ity in China had better islet function and higher frequency 
of GADA. Moreover, we found that HLA-A*11:01- 
DRB1*09:01was associated with 2Ab+ patients. 
Slight ethnic differences can be found in LADA patients 
between our data and the studies in the West (Hawa et al., 
2013). For example, the age of onset is older and the level 
of LDL was higher in the East. BMI is the major difference 
between the Westerners and Asians.  
Although one of the hallmarks of T1DM is the presence 
of one or several autoantibodies, it is well recognized that 
there is a subset of presumed T1DM patients who are auto-
antibody-negative at diagnosis. The proportion of cases 
presented with DKA and the mean hemoglobin A1C 
(HbA1C) levels was higher in these autoantibody-negative 
subjects than that in USA (Gerard-Gonzalez et al., 2013). 
Meanwhile, the beta-cell function was similar to that of 
LADA without the probably metabolic protective factors, 
which might due to the absence of autoantibodies or the 
moderately destructive effect of yet-to-be identified autoan-
tibodies. 
Although the autoantibody was a risk factor to the loss of 
islet function, there were still some differences. While fast-
ing C-peptide was closely correlated to glucagon-stimulated 
C-peptide, AUC seemed to be a more stable marker to indi-
cate the stimulated islet function than fasting islet function 
(Gjessing et al., 1987; Besser et al., 2013). The different 
prevalence of GADA, ZnT8A, IA2A between fasting 
C-peptide and AUC could be explained by that GADA was 
associated with stimulated islet function, while ZNT8A, 
IA2A were associated with fasting islet function. This ob-
servation was in line with previous report, the patients with 
GADA had a more rapid decline in residual beta-cell func-
tion, while GADA negative patients were more likely to 
exhibit a remission phase (Mortensen et al., 2010). 
There were further limitations to this study. First, the 
strongest genetic association for T1DM is HLA CLASS II 
alleles, especially HLA-DQA1 and DQB1. However, we 
only tested HLA-A and HLA-DR alleles under limited con-
ditions in our laboratory, so we will further genotype 
HLA-DQA1 and DQB1 in the follow-up analysis. Besides, 
the GADA, IA2A and ZnT8A were not quantified with titer. 
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Second, not all patients conducted a 3-hour mixed-meal 
tolerance test at baseline. Indeed, they took a 2-hour 
mixed-meal tolerance test instead. 
It was the first time to report the prevalence of type 1 di-
abetes in East China. It included 1,291 T1D patients from 
22 hospitals in Jiangsu Province. We assessed GADA, 
IA2A and ZnT8A with RIA, and demonstrated their associ-
ation with heterogeneity of islet failure and clinical pheno-
types. Patients with one or several antibodies positivity re-
flected that they were suffered autoimmune attack to their 
pancreas. And sometimes it might occur before detection. 
As a result, their loss of beta cell function was significantly 
greater than those without autoantibodies.  
MATERIALS AND METHODS 
Subjects 
Sera samples were obtained from 1,291 (49.3% female) 
Chinese T1DM patients who were identified and examined 
at 22 centers from 2009 to 2015. Individuals with T1DM 
were diagnosed according to the criteria of World Health 
Organization (WHO) and The American Diabetes Associa-
tion (ADA). Definite T1DM requires that at least one of the 
following is present: (i) age less than 10 year at diagnosis; 
(ii) positive pancreatic autoantibodies at any time (GADA, 
IA-2A, ICA, or ZnT8A) or positive anti-insulin autoanti-
body at diagnosis only (within 10 d of starting insulin); or 
(iii) the presence of two or more of the following clinical 
indicators suggestive of T1DM: (1) age at diagnosis less 
than 40 year; (2) nonobese at diagnosis according to body 
mass index (< 95th percentile pediatric and < 30 kg m2 
adult); (3) diabetic ketoacidosis (DKA) at any time; (4) 
plasma C-peptide level below 0.8 ng mL1 (with blood glu-
cose > 80 mg dL1 if available) at any time; and (5) family 
history of T1DM in a first-degree relative (parent, sibling, 
or child) (Beck et al., 2012). The mean age at onset and the 
mean duration of diabetes was 27.6±17.7 years (mean±SD) 
and 33.2±69.2 months, respectively. To further explore the 
impact of the autoimmune and clinical factors, we divided 
these patients into the following four subgroups: (i) classic 
T1DM patients with at least two autoantibodies positive 
(2Ab+); (ii) classic T1DM patients with just one autoanti-
body positive (1Ab+); (iii) classic T1DM patients with au-
toantibody negative (Ab); (iv) latent autoimmune diabetes 
of adult (LADA). The diagnosis of LADA is based on three 
criteria: (1) diagnosed over the age of 30 years; (2) the 
presence of circulating islet autoantibodies (GADA, IA-2A, 
ICA, or ZnT8A); and (3) lack of requirement of insulin for 
at least six months after diagnosis (Fourlanos et al., 2005). 
A written form was filled in for each patient including 
name, age, sex, age at onset, duration of diabetes, anthro-
pometric data, clinical manifestation, birth weight, way of 
delivery, feeding pattern, family history of diabetes, known 
complications and other illnesses. Characteristics of study 
participants in the current study are given in Table 2. All 
subjects gave informed consent, and the protocol was ap-
proved by the local Ethics Committee and was carried out in 
agreement with the Declaration of Helsinki as revised in 
2000. 
Laboratory data 
The hospital-based laboratory services (including blood 
glucose, HbA1c, lipids, C-peptide, insulin, islet autoanti-
bodies) were available. Patients attended the centers in a 
fasted state and blood was taken into plain tubes. Lipids and 
glucose levels were measured on an automatic enzymatic 
analyzer (Beckman Coulter, USA), while islet autoantibod-
ies (including ICA and IAA) were determined by ELISA 
(Euroimmun Medizinische Labordiagnostika AG, Germany; 
Biomerica, USA). 
A mixed-meal tolerance test was performed after a time 
interval of treatment with insulin until the fasting blood 
glucose lower than 10.0 mmol L1. Plasma levels of glu-
cose, insulin and C-peptide were measured at baseline and 
30, 60, 120 and 180 min after mixed-meal consumption. 
Plasma insulin and C-peptide concentrations were measured 
by chemiluminescence (Roche Diagnostics, Switzerland). 
The 3-h C-peptide area under the curve (AUC) was calcu-
lated using the trapezoidal rule over the 3-h period (0–180 
min). 
Blood taken into the plain tubes were centrifuged at 
350×g and stored frozen at 80°C. Later, RIA was used for 
detecting ZnT8A, GADA and IA2A as previously described 
(Gu et al., 2011). Briefly, human 35S-labeled recombinant 
antigens were produced in an in vitro-coupled transcription 
and translation system with SP6 (GAD, IA2) or T7 
(ZnT8A) RNA polymerase and nuclease-treated rabbit re-
ticulocyte lysate (Promega, USA). Sera (5 μL) were incu-
bated with 35 S-antigens (20 000 of TCA-precipitable ra-
dioactivity). After an overnight incubation at 4°C, anti-
body-bound 35 S-antigens were separated from unbound 
antigen by precipitation with Protein A Sepharose (GE 
Amersham Biosciences, USA). The immuno-precipitated 
radioactivity was counted on a Wallac Microbeta Liquid 
Scintillation Counter (Perkin Elmer Life and Analytical 
Sciences, USA). 
Antibody levels were expressed as a relative immuno- 
precipitation index, which is defined as (sample-negative 
control)/(positive controlnegative control). The cut-off for 
positivity for ZnT8A, GADA and IA2A was defined as a 
value above 0.015, 0.048 and 0.018 respectively, based on 
the 99th percentile of 102, 315 and 218 healthy control sub-
jects (non-diabetic individuals without known autoimmune 
disease and no family history of diabetes). The GADA, 
IA2A, ZnT8 assays achieved a laboratory-defined sensitivi-
ty of 64%, 64% and 36%, with 97.8%, 100% and 97.8% 
specificity, respectively in Islet Antibody Standardization 
Program of 2013. 
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Statistical Analysis 
Statistical analysis was performed using the SPSS program 
(version 21.0; SPSS, USA). Values are reported as 
means±SEM or means±SD. For categorical variables, dif-
ferences were compared with the 2 or Fisher’s exact test if 
the expected number of subjects in any cell was less than 
five. For continuous variables with normal distribution of 
the values, differences were tested using the Student’s t-test 
or ANOVA test, while nonparametric tests were used for 
skewed data. Binary logistic regression and multivariate 
logistic regression analyses were used to explore the rela-
tionship between islet autoantibodies and islet function in 
patients with type 1 diabetes. P values <0.05 (two-tailed 
significance) were considered statistically significant. 
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